Literature DB >> 17701010

A patient with gastric cancer and liver metastases successfully treated with combination chemotherapy including S-1.

Rieko Nakamura1, Yoshiro Saikawa, Koushi Kumagai, Tsuyoshi Kiyota, Masaki Ohashi, Masashi Yoshida, Tetsuro Kubota, Koichiro Kumai, Masaki Kitajima.   

Abstract

We report the case of a 62-year-old man with advanced gastric cancer and multiple liver metastases who was successfully treated with combined chemotherapy including S-1. The patient was clinically diagnosed with stage IV (T3 N2 H1 P0) disease and was initially treated with 100 mg/body per day S-1 administered orally for 21 days and 10 mg/body per day cisplatin (CDDP) infused on days 1-5, 8-12, and 15-19. This chemotherapy resulted in significant reduction of the liver and gastric tumors. After receiving additional CDDP/S-1 administration as an outpatient, the patient's liver masses disappeared as shown on abdominal computed tomography (CT). With the patient's desire and informed consent, he underwent curative surgery with total gastrectomy, D1+alpha lymph node dissection, and partial resection of liver S4. After discharge without any surgical complication, CT revealed regrowth of the S4 liver mass, and combined docetaxel and CDDP was selected as second-line chemotherapy with local radiation therapy against the hepatic metastasis. Additionally, a third regimen with irinotecan and S-1 was given. At 2 years 7 months after the initial treatment, no sign of cancer (including liver metastasis and peritoneal dissemination) has been identified by radiological follow-up examinations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17701010     DOI: 10.1007/s10147-006-0648-4

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  26 in total

1.  Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined chemotherapy of S-1 and low-dose cisplatin: report of a case.

Authors:  M Iwahashi; M Nakamori; M Tani; H Yamaue; S Sakaguchi; M Nakamura; K Ueda; M Ichiro; E Nishino; H Tanimura
Journal:  Oncology       Date:  2001       Impact factor: 2.935

2.  Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study.

Authors:  G P Stathopoulos; S K Rigatos; G Fountzilas; A Polyzos; J G Stathopoulos
Journal:  Oncol Rep       Date:  2002 Jan-Feb       Impact factor: 3.906

3.  Benefits and limits of hepatic resection for gastric metastases.

Authors:  S Ambiru; M Miyazaki; H Ito; K Nakagawa; H Shimizu; H Yoshidome; Y Shimizu; N Nakajima
Journal:  Am J Surg       Date:  2001-03       Impact factor: 2.565

4.  Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.

Authors:  U Vanhoefer; P Rougier; H Wilke; M P Ducreux; A J Lacave; E Van Cutsem; M Planker; J G Santos; P Piedbois; B Paillot; H Bodenstein; H J Schmoll; H Bleiberg; B Nordlinger; M L Couvreur; B Baron; J A Wils
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

5.  Preoperative combination chemotherapy with S-1 and low dose cisplatin against highly advanced gastric carcinoma.

Authors:  Yoshiro Saikawa; Yoshikiyo Akasaka; Toshio Kanai; Yoshihide Otani; Koichiro Kumai; Tetsuro Kubota; Masaki Kitajima
Journal:  Oncol Rep       Date:  2003 Mar-Apr       Impact factor: 3.906

6.  Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism.

Authors:  Shingo Maeda; Tsudoi Sugiura; Yoshiro Saikawa; Tetsuro Kubota; Yoshihide Otani; Koichiro Kumai; Masaki Kitajima
Journal:  Cancer Sci       Date:  2004-08       Impact factor: 6.716

7.  Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer.

Authors:  Shunichi Tsujitani; Kenji Fukuda; Nobuaki Kaibara
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

Review 8.  Docetaxel-based chemotherapy in the treatment of gastric cancer.

Authors:  A D Roth; J Ajani
Journal:  Ann Oncol       Date:  2003       Impact factor: 32.976

9.  Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity.

Authors:  S Mullany; P A Svingen; S H Kaufmann; C Erlichman
Journal:  Cancer Chemother Pharmacol       Date:  1998       Impact factor: 3.333

10.  Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

Authors:  Atsushi Ohtsu; Yasuhiro Shimada; Kuniaki Shirao; Narikazu Boku; Ichinosuke Hyodo; Hiroshi Saito; Noboru Yamamichi; Yoshinori Miyata; Nobumasa Ikeda; Seiichiro Yamamoto; Haruhiko Fukuda; Shigeaki Yoshida
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

View more
  1 in total

1.  Complete response of liver metastasis of gastric cancer treated by s-1 chemoradiotherapy: a case report.

Authors:  Tomonori Miyazawa; Kazuyu Ebe; Norihiko Koide; Nobuhiro Fujita
Journal:  Case Rep Oncol Med       Date:  2012-08-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.